Cyclobenzaprine, widely known by the brand name Flexeril, is a skeletal muscle relaxant commonly prescribed for short-term pain relief and muscle spasms. Although it’s designed for brief therapeutic use, some people develop physical dependence on the drug, making discontinuation more complex than simply stopping the medication.

This page outlines what Flexeril withdrawal involves, why it happens, the symptoms people commonly experience, and how long the process typically takes.

What Is Flexeril Withdrawal?

Flexeril withdrawal refers to the physical and psychological symptoms that can emerge when someone reduces or stops cyclobenzaprine after prolonged or heavy use. Because cyclobenzaprine acts on the CNS (central nervous system) in ways similar to tricyclic antidepressants, the withdrawal experience can mirror what people encounter when discontinuing that class of medication [1].

Withdrawal from Flexeril is generally mild compared to stopping substances like opioids or benzodiazepines. Most people experience manageable discomfort rather than a medical crisis. That said, mild doesn’t mean trivial, and individuals who have been taking higher doses, using the drug for extended periods, or combining it with other substances face a more difficult path.

What Causes Withdrawal from Flexeril?

Physical dependence drives withdrawal [2]. When someone takes cyclobenzaprine consistently over weeks or months, the CNS adapts. Neurotransmitter systems adjust their baseline activity in response to the drug’s presence. The brain, in effect, recalibrates to function with cyclobenzaprine on board.

Remove that chemical input suddenly, and the system lurches. Processes that had been suppressed or amplified to compensate for the drug now overcorrect. That overcorrection produces withdrawal symptoms.

Stopping cyclobenzaprine abruptly is the most direct path to pronounced withdrawal. The body has no time to readjust, so symptoms emerge quickly and with more intensity. A gradual reduction, by contrast, allows the nervous system to adapt incrementally, smoothing the process.

Dependence and addiction are distinct conditions, although they sometimes coexist. Dependence simply means the body has adjusted to the drug’s presence. Addiction involves compulsive use despite adverse outcomes, cravings, and loss of control. Someone can be physically dependent on Flexeril after a legitimate prescription without meeting criteria for addiction.

Cyclobenzaprine may be misused recreationally, often combined with alcohol, benzos, or barbiturates to amplify sedation and euphoria [3]. Taking more than therapeutic doses of this medication significantly increases both the risk of dependence and the difficulty of withdrawal.

What Are the Common Symptoms of Flexeril Withdrawal?

The core symptoms of cyclobenzaprine withdrawal are generally consistent across reported cases, although individual experience varies considerably. Some people sail through discontinuation with little more than a few days of fatigue. Others find the nausea and sleep disruption pronounced enough to interfere with daily functioning.

The most commonly documented cyclobenzaprine withdrawal symptoms include nausea, headache, and a general sense of malaise or fatigue. These physical symptoms often emerge within a few days of the last dose and can range from minor discomfort to genuinely disruptive. For someone who used the drug as directed for a few weeks, symptoms typically stay mild and resolve without intervention. For someone who took higher doses or mixed cyclobenzaprine with other substances, the experience looks different.

Other common Flexeril withdrawal symptoms include:

• Chills.

• Sweating.

• Muscle aches.

• Heightened anxiety.

• Restlessness.

• Irritability.

• Mood swings.

• Sleep disruption and insomnia.

People who have been combining cyclobenzaprine with other CNS depressants face additional issues. Withdrawal from muscle relaxers used alongside alcohol or benzodiazepines can trigger more severe symptoms, since the body is adjusting to the removal of multiple substances simultaneously. Alcohol and benzo withdrawal carry their own serious risks, including life-threatening seizures, and require medical supervision.

Flexeril withdrawal is seldom dangerous on its own. The primary concern is discomfort significant enough to push someone toward continued use just to escape the symptoms, which can fuel a cycle of dependence.

Factors That Affect the Intensity of Withdrawal Symptoms

The nature of Flexeril withdrawal symptoms depends on risk factors such as:

• Dosage and duration of use – Higher doses taken over longer periods produce stronger physical dependence. Someone who took 5mg for 2 weeks faces a very different withdrawal than someone who used 30mg extended-release capsules for several months.

• Method of discontinuation – Whether someone tapers off gradually or stops abruptly matters enormously. Stopping cyclobenzaprine suddenly forces the CNS to adapt rapidly, amplifying withdrawal symptoms. A supervised cyclobenzaprine taper-off schedule, where doses are reduced incrementally over days or weeks, minimizes that shock.

• Concurrent substance use – Mixing cyclobenzaprine with alcohol, barbiturates, or benzodiazepines raises the stakes. These combinations do more than intensify the sedative effects. They trigger more complex dependence. Withdrawal from muscle relaxers used in combination with other CNS depressants is much harder to manage and may require medical detox [4].

• Individual biology ­– Metabolic rate, liver function, genetics, and neurochemistry all influence how the body processes and eliminates cyclobenzaprine, and how dramatically it responds to its absence. Mental health history also plays a role, since underlying anxiety or depression can compound withdrawal discomfort. Someone already managing an anxiety disorder may find that withdrawal symptoms intensify their baseline symptoms, requiring careful clinical attention.

• Overall health status – Chronic medical conditions, nutritional deficiencies, and sleep disorders can all make withdrawal more difficult to tolerate. Poor sleep, in particular, can amplify many other withdrawal symptoms and slow the overall recovery process.

How Long Does Withdrawal Last?

The Flexeril withdrawal timeline unfolds across several stages, although the overall duration varies from person to person.

1. Initial phase (24 to 72 hours after the last dose) – Symptoms typically begin within 1 to 3 days of stopping or significantly reducing cyclobenzaprine. Early symptoms often include headaches, nausea, and fatigue. The onset can feel gradual at first, becoming more noticeable by the second or third day.

2. Peak phase (days 3 to 7) – Withdrawal symptoms generally peak within the first week. This is when discomfort tends to be most pronounced. Nausea, muscle aches, sleep difficulty, and mood-related symptoms like irritability or anxiety are most likely to peak during this window. People who stopped abruptly may notice sharper, more uncomfortable symptoms than those who tapered.

3. Resolution phase (week 2 and beyond) – For most individuals, the acute withdrawal period resolves within 1 to 2 weeks. Symptoms diminish gradually. Some people experience lingering fatigue or mild sleep disruption beyond that window, particularly those who used higher doses for extended periods.

Anyone asking whether you can withdraw from muscle relaxers should know the honest answer is yes, and the timeline above reflects what that typically looks like with cyclobenzaprine. However, for people who combined the drug with other substances, or who used very high doses, the timeline may extend, and some symptoms associated with those other substances may overlap and complicate the picture.

A physician can develop a tapering plan suited to individual circumstances. This is especially important for anyone who has been misusing the drug or taking it alongside other substances.

Getting Help for Flexeril Misuse

Muscle relaxer withdrawal symptoms, while generally manageable, can be uncomfortable enough to discourage people from discontinuing the drug without support. Some individuals continue using cyclobenzaprine primarily to avoid withdrawal discomfort rather than for therapeutic benefit. When cyclobenzaprine use has crossed into misuse or addiction, professional treatment makes a measurable difference in both safety and outcomes.

Treatment for Flexeril misuse typically involves medical detox when indicated, particularly for people using multiple substances simultaneously. Individual therapy, group counseling, and relapse prevention planning follow. Programs like IOP (intensive outpatient programs) and PHP (partial hospitalization programs) offer structured care without requiring a full residential commitment, making treatment accessible for people with work or family obligations.

Medication-assisted approaches may address co-occurring substance use disorders when clinically appropriate. A thorough clinical assessment identifies the most appropriate level of care for each person’s unique situation.

FAQs

Do you have withdrawal from Flexeril?

Yes. While not a controlled substance, Flexeril does cause withdrawal symptoms, especially for people who have used cyclobenzaprine for pain management at higher doses, for extended periods, or in combination with other substances. Symptoms are typically mild to moderate and include nausea, headache, and fatigue.

What are four of the withdrawal symptoms?

Four commonly reported cyclobenzaprine withdrawal symptoms are nausea, headache, malaise, and insomnia. Some people also experience chills, muscle aches, anxiety, and irritability, particularly those with heavier or longer-term use patterns.

Does Flexeril need to be tapered off?

For most people, gradual tapering is the preferred approach to stopping cyclobenzaprine, especially after extended use. A physician can design a cyclobenzaprine taper-off schedule that reduces the dose incrementally over days or weeks, helping individuals manage psychological symptoms and making the process safer and more manageable.

What are the stages of withdrawal?

Flexeril withdrawal generally progresses through 3 stages: an early phase beginning within 1 to 3 days of the last dose, a peak phase around days 3 to 7 when symptoms are most intense, and a resolution phase during the second week when symptoms gradually subside. The overall Flexeril withdrawal timeline typically spans 1 to 2 weeks, although individual factors like dose, duration of use, and concurrent substance use can extend that window.

Get Cyclobenzaprine Addiction Treatment at District Behavioral Health Group

We deliver effective, evidence-based treatment for even severe addiction to prescription drugs and other medications at District Behavioral Health Group. Access evidence-based care across the full continuum via our national network of treatment providers.

Our addiction and mental health treatment programming includes:

• Detox – Medically supervised detox blending FDA-approved drugs and talk therapies, streamlining the withdrawal process and preparing you for ongoing treatment for addiction to prescription medications.

• Crisis intervention/stabilization – Continuous emotional and medical support to help individuals in crisis restore stability and functioning.

• Inpatient/residential programs – 24-hour inpatient care, with personalized therapies, clinical support, structured routines, and support groups in a trigger-free setting.

• PHPs (partial hospitalization programs) – Full-time outpatient treatment programs, providing immersive counseling, group therapy, and tailored support.

• IOPs (intensive outpatient programs) – Part-time outpatient treatment programs, offering accountability and structure while you continue at home, work, or school.

• OP – outpatient programs) ­– Ongoing therapy sessions to help ease the transition to independent living and minimize the risk of relapse.

Learn more about our individualized addiction and mental health treatment programs by calling admissions today at 561-919-6792.

Sources

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC3669814/

[2] https://pmc.ncbi.nlm.nih.gov/articles/PMC8583742/

[3] https://pmc.ncbi.nlm.nih.gov/articles/PMC12497723/

[4] https://www.ncbi.nlm.nih.gov/books/NBK64119